Achilles Therapeutics (NasdaqGS:ACHL) - Share price, News & Analysis

ACHL fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ACHL Stock Overview

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.

Risk Analysis

Earnings are forecast to decline by an average of 23.9% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($94M)

Achilles Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Achilles Therapeutics
Historical stock prices
Current Share Price	US$2.35
52 Week High	US$14.39
52 Week Low	US$1.84
Beta	0
1 Month Change	-0.84%
3 Month Change	-33.62%
1 Year Change	-81.64%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-85.80%

Recent News & Updates

Apr 13

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

	ACHL	US Biotechs	US Market
7D	14.1%	4.8%	0.7%
1Y	-81.6%	-22.0%	-10.8%

Return vs Industry: ACHL underperformed the US Biotechs industry which returned -22% over the past year.

Return vs Market: ACHL underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is ACHL's price volatile compared to industry and market?
ACHL volatility
ACHL Average Weekly Movement	10.0%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: ACHL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ACHL's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	247	Iraj Ali	https://www.achillestx.com

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.

Achilles Therapeutics Fundamentals Summary

How do Achilles Therapeutics's earnings and revenue compare to its market cap?
ACHL fundamental statistics
Market Cap	US$93.73m
Earnings (TTM)	-US$64.69m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.5x

P/E Ratio

Is ACHL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACHL income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$64.69m
Earnings	-US$64.69m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.59
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ACHL perform over the long term?

See historical performance and comparison

Valuation

Is Achilles Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.36x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACHL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACHL's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ACHL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ACHL is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACHL's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ACHL is good value based on its PB Ratio (0.4x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Achilles Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-23.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACHL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACHL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACHL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ACHL's revenue is forecast to grow faster than the US market.

High Growth Revenue: ACHL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACHL's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Achilles Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-58.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACHL is currently unprofitable.

Growing Profit Margin: ACHL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ACHL is unprofitable, and losses have increased over the past 5 years at a rate of 58.5% per year.

Accelerating Growth: Unable to compare ACHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACHL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: ACHL has a negative Return on Equity (-24.28%), as it is currently unprofitable.

Financial Health

How is Achilles Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ACHL's short term assets ($259.0M) exceed its short term liabilities ($17.9M).

Long Term Liabilities: ACHL's short term assets ($259.0M) exceed its long term liabilities ($7.9M).

Debt to Equity History and Analysis

Debt Level: ACHL is debt free.

Reducing Debt: ACHL had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACHL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ACHL has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 65.5% each year.

Dividend

What is Achilles Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACHL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACHL has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure

CEO

Iraj Ali (45 yo)

4.33yrs

Tenure

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....

Leadership Team

Experienced Management: ACHL's management team is considered experienced (4.3 years average tenure).

Board Members

Experienced Board: ACHL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31